WallStSmart

Alcon AG (ALC)vsNephros Inc (NEPH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Alcon AG generates 55506% more annual revenue ($10.63B vs $19.12M). ALC leads profitability with a 7.7% profit margin vs 4.1%. ALC trades at a lower P/E of 40.7x. ALC earns a higher WallStSmart Score of 49/100 (D+).

ALC

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 4.5Value: 3.3Quality: 6.8
Piotroski: 3/9

NEPH

Avoid

32

out of 100

Grade: F

Growth: 6.0Profit: 4.5Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: -10.50
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALCSignificantly Overvalued (-24.0%)

Margin of Safety

-24.0%

Fair Value

$64.04

Current Price

$66.81

$2.77 premium

UndervaluedFair: $64.04Overvalued
NEPHUndervalued (+6.9%)

Margin of Safety

+6.9%

Fair Value

$4.34

Current Price

$3.42

$0.92 discount

UndervaluedFair: $4.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALC2 strengths · Avg: 9.5/10
Price/BookValuation
1.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.249/10

Conservative balance sheet, low leverage

NEPH1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0910/10

Conservative balance sheet, low leverage

Areas to Watch

ALC4 concerns · Avg: 3.3/10
PEG RatioValuation
1.544/10

Expensive relative to growth rate

Return on EquityProfitability
3.7%3/10

ROE of 3.7% — below average capital efficiency

Profit MarginProfitability
7.7%3/10

7.7% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

NEPH4 concerns · Avg: 3.0/10
Market CapQuality
$36.80M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
7.3%3/10

ROE of 7.3% — below average capital efficiency

Profit MarginProfitability
4.1%3/10

4.1% margin — thin

Operating MarginProfitability
1.9%3/10

Operating margin of 1.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : ALC

The strongest argument for ALC centers on Price/Book, Debt/Equity.

Bull Case : NEPH

The strongest argument for NEPH centers on Debt/Equity.

Bear Case : ALC

The primary concerns for ALC are PEG Ratio, Return on Equity, Profit Margin. A P/E of 40.7x leaves little room for execution misses.

Bear Case : NEPH

The primary concerns for NEPH are Market Cap, Return on Equity, Profit Margin. A P/E of 48.4x leaves little room for execution misses. Thin 4.1% margins leave little buffer for downturns.

Key Dynamics to Monitor

NEPH carries more volatility with a beta of 1.50 — expect wider price swings.

ALC is growing revenue faster at 9.4% — sustainability is the question.

ALC generates stronger free cash flow (274M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ALC scores higher overall (49/100 vs 32/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alcon AG

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Alcon, Inc., an eye care company, researches, develops, manufactures, distributes and sells eye care products for eye care professionals and their patients around the world. The company is headquartered in Geneva, Switzerland.

Visit Website →

Nephros Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Nephros, Inc., a commercial stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company is headquartered in South Orange, New Jersey.

Want to dig deeper into these stocks?